Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2021 Oct 7;138(14):1208-1209.
doi: 10.1182/blood.2021013434.

One step at a time

Hélène Schoemans  1   2 , Per Ljungman  3
Affiliations
Editorial

One step at a time

Hélène Schoemans et al. Blood. .
No abstract available

PubMed Disclaimer

Conflict of interest statement

Conflict-of-interest disclosure: H.S. reports personal fees and nonfinancial support from Incyte; grants, personal fees, and nonfinancial support from Novartis and BHS (Belgian Hematological Society); personal fees from, Janssen, Jazz Pharmaceuticals, and Takeda; and nonfinancial support from Gilead, the EBMT (European Society for Blood and Marrow transplantation), and the CIBMTR (Center for International Bone Marrow Transplantation Research) outside the submitted work. P.L. reports grants from SciLife Laboratory/KAW Foundation during the conduct of the study; grants and personal fees from MSD; and personal fees from AiCuris, Takeda, Pfizer, BMS, and OctaPharma, outside the submitted work.

Figures

None
Seroconversion rates of cellular therapy recipients after the second dose of COVID-19 vaccine (the number of icons reflects the total number of patients evaluated in Dhakal et al). Purple, positive seroconversion; yellow, no seroconversion.
See this image and copyright information in PMC

Comment on

References

    1. Dhakal B, Abedin SM, Fenske TS, et al. . Response to SARS-CoV-2 vaccination in patients after hematopoietic cell transplantation and CAR-T cell therapy. Blood. 2021;138(14):1278-1281. - PMC - PubMed
    1. Goshen-Lago T, Waldhorn I, Holland R, et al. . Serologic Status and Toxic Effects of the SARS-CoV-2 BNT162b2 Vaccine in Patients Undergoing Treatment for Cancer [published online ahead of print 8 July 2021]. JAMA Oncol. - PMC - PubMed
    1. Thakkar A, Gonzalez-Lugo JD, Goradia N, et al. . Seroconversion rates following COVID-19 vaccination among patients with cancer. Cancer Cell. 2021;39(8):1081-1090.e2. - PMC - PubMed
    1. Redjoul R, Le Bouter A, Beckerich F, Fourati S, Maury S. Antibody response after second BNT162b2 dose in allogeneic HSCT recipients. Lancet. 2021;398(10297):298-299. - PMC - PubMed
    1. Ram R, Hagin D, Kikozashvilli N, et al. . Safety and Immunogenicity of the BNT162b2 mRNA COVID-19 Vaccine in Patients after Allogeneic HCT or CD19based CART therapy-A Single-Center Prospective Cohort Study [published online ahead of print 30 June 2021]. Transplant Cell Ther. - PMC - PubMed